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Abstract
Introduction: Overexpression of the oxygen-responsive transcription factor hypoxia-inducible factor 1a (HIF-1a)
correlates with poor prognosis in breast cancer patients. The mouse mammary tumor virus polyoma virus middle T
(MMTV-PyMT) mouse is a widely utilized preclinical mouse model that resembles human luminal breast cancer and
is highly metastatic. Prior studies in which the PyMT model was used demonstrated that HIF-1a is essential to
promoting carcinoma onset and lung metastasis, although no differences in primary tumor end point size were
observed. Using a refined model system, we investigated whether HIF-1a is directly implicated in the regulation of
tumor-initiating cells (TICs) in breast cancer.
Methods: Mammary tumor epithelial cells were created from MMTV-PyMT mice harboring conditional alleles of
Hif1a, followed by transduction ex vivo with either adenovirus b-galactosidase or adenovirus Cre to generate wild-
type (WT) and HIF-1a-null (KO) cells, respectively. The impact of HIF-1a deletion on tumor-initiating potential was
investigated using tumorsphere assays, limiting dilution transplantation and gene expression analysis.
Results: Efficient deletion of HIF-1a reduced primary tumor growth and suppressed lung metastases, prolonging
survival. Loss of HIF-1a led to reduced expression of markers of the basal lineage (K5/K14) in cells and tumors and
of multiple genes involved in the epithelial-to-mesenchymal transition. HIF-1a also enhanced tumorsphere
formation at normoxia and hypoxia. Decreased expression of several genes in the Notch pathway as well as Vegf
and Prominin-1 (CD133)was observed in response to Hif1a deletion. Immunohistochemistry confirmed that CD133
expression was reduced in KO cells and in tumorspheres. Tumorsphere formation was enhanced in CD133hi versus
CD133neg cells sorted from PyMT tumors. Limiting dilution transplantation of WT and KO tumor cells into
immunocompetent recipients revealed > 30-fold enrichment of TICs in WT cells.
Conclusion: These results demonstrate that HIF-1a plays a key role in promoting primary mammary tumor growth
and metastasis, in part through regulation of TICs. HIF-1a regulates expression of several members of the Notch
pathway, CD133 and markers of the basal lineage in mammary tumors. Our results suggest that CD133, which has
not been profiled extensively in breast cancer, may be a useful marker of TICs in the PyMT mouse model. These
data reveal for the first time that HIF-1a directly regulates breast TIC activity in vivo.
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Introduction
A hallmark of most solid tumors, hypoxic regions are
associated with resistance to radiation and chemother-
apy [1,2]. O2 tension in advanced breast cancers can be
as low as 0.1% to 1% O2 [3], a range commonly used to
model tissue hypoxia in vitro. The oxygen-responsive
hypoxia-inducible factor 1a (HIF-1a) protein, a master
regulator of the hypoxic response [4], is overexpressed
in a variety of carcinomas and their metastases, includ-
ing breast cancer [5]. A majority of ductal carcinoma in
situ and almost all poorly differentiated, invasive breast
carcinomas overexpress HIF-1a [6]. Moreover, HIF-1a
promotes multiple steps of the metastasis program [7].
Either the overexpression of HIF-1a protein or the
enrichment of a hypoxic gene signature in the primary
tumor correlates with poor prognosis and decreased sur-
vival in breast cancer patients [8,9].
Breast cancer cells that exhibit properties of cancer
stem cells (CSCs), also referred to as tumor-initiating
cells (TICs), are more resistant than bulk tumor cells to
therapeutic intervention, including radiation and DNA-
damaging drugs [10-12]. Hypoxic culture promotes self-
renewal of several cell types, including neurospheres,
hematopoietic stem cells (HSCs) and embryonic stem
(ES) cells [13]. HIF-1a is also necessary in vivo for
HSCs because its deletion causes stem cell exhaustion
[14].
Accumulating evidence supports the hypothesis that
stem cells and TICs exist in a hypoxic niche microenvir-
onment [13]. The direct relationship of the hypoxic
response to TIC activity has been demonstrated in adult
glioma, human acute myeloid leukemia (AML) and mur-
ine lymphoma [15,16]. In gliomas, expression of HIF2A
mRNA was enriched, and knockdown of HIF2A, but not
HIF1A, reduced TIC activity in patient xenografts [15].
In contrast, HIF-1a was found to be essential for main-
taining TIC activity in a syngeneic rodent transplant
model of lymphoma and in AML patient xenografts
through regulation of the Notch pathway [16]. Interest-
ingly, in gliomas, the TIC population was enriched via
cell sorting based on the expression of a single cell sur-
face marker, CD133 (PROM1). PROM1, a transmem-
brane protein without a known ligand, is a hypoxia-
responsive protein regulated by HIF-1a [17,18].
Several studies have shown that the population of
breast tumor cells with the ability to self-renew is
enriched with the ability to initiate tumorigenesis in vivo
[19-22]. Furthermore, TICs may drive metastasis [23,24].
The mouse mammary tumor virus polyoma virus middle
T (MMTV-PyMT) mouse model is one of the most
commonly utilized preclinical mouse models in breast
cancer research because tumor latency is short and
there is a high frequency of metastasis to the lung [25].
Whole-genome array profiling indicates that PyMT
tumors most closely resemble the luminal B subtype of
human breast cancer [26], although end-stage PyMT
tumors are estrogen and progesterone receptor (ER and
PR)-negative [25].
Moreover, the specific contribution of HIF-1a in regu-
lating TICs in breast cancer remains undefined, particu-
larly in the context of syngeneic rodent models that
recapitulate the breast cancer microenvironment. It has
previously been shown that conditional deletion of
Hif1a in PyMT+ tumors by crosses to mice expressing
MMTV-Cre delayed the onset of palpable tumors,
delayed the progression of hyperplasias to carcinomas
and reduced lung metastases [27]. We have now created
an improved model system in which Hif1a is efficiently
deleted in the mammary tumor epithelium via ex vivo
viral transduction with Cre recombinase prior to the
injection of mammary tumor cells to the cleared fat
pads of recipient mice. Validating the use of a transplan-
tation paradigm in lieu of intact transgenic mice, pre-
vious studies have shown that when isolated PyMT
tumor cells are serially regenerated as tumors in recipi-
ent mice the morphology and gene expression profiles
are similar to the tumors found in the transgenic mouse
[28].
Using these novel HIF-1a wild-type (WT) and HIF-
1a-null (KO) mammary tumor epithelial cells (MTECs),
we demonstrate that HIF-1a prominently augments pri-
mary tumor growth and lung metastasis and accelerates
relapse due to metastasis. Furthermore, we show for the
first time that HIF-1a promotes mammary tumorsphere
formation and enhances TIC frequency in vivo, in part
by regulation of the expression of markers associated
with the basal lineage, the Notch pathway and CD133.
Together these data indicate that suppressing the
hypoxic response may be beneficial not only by reducing
primary tumor mass but also by suppressing the breast




Mice harboring two alleles of exon 2 of Hif1a flanked by
loxP sites (double-floxed, DF) were provided by Dr Ran-
dall Johnson (University of California San Diego) on a
mixed genetic background (129Sv-C57BL/6 [29]). Hif1a
stock mice were first backcrossed to the FVB/Nj strain
(The Jackson Laboratory, Bar Harbor, ME, USA) for 11
generations prior to being bred to MMTV-PyMT trans-
genic mice obtained from Dr Kent Hunter (National
Cancer Institute, Frederick, MD, USA), which had pre-
viously been backcrossed to the FVB/Nj strain. Lung
metastasis induced by the PyMT transgene is highly
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penetrant in the FVB/Nj background [30]. All proce-
dures were approved by Institutional Animal Care and
Use Committee at the University of Tennessee Health
Science Center.
Establishing Hif1a wild-type and knockout mammary
tumor epithelial cells
Several mammary tumors (> 500 mm3) were isolated
from Hif1a DF, PyMT+ bigenic female mice. Tumors
were chopped with scalpels and then with razor blades,
and the paste was digested with 1 mg/ml collagenase
type III (Worthington Biochemical Corp, Lakewood, NJ,
USA) in RPMI media containing 5% fetal bovine serum
(FBS) (5 ml/g tissue) for 2 hours at 37°C. Organoids
were pelleted at 1,100 rpm, washed four times with
digestion buffer and then plated into standard tissue
culture plates in plating medium as described previously
[31]. After 48 to 72 hours, the plating medium was
switched to complete mammary epithelial cell growth
medium (GIBCO DMEM: Nutrient Mixture F-12
(DMEM/F-12; Invitrogen, Carlsbad, CA, USA), 5% FBS,
5 μg/ml insulin (Sigma-Aldrich, St Louis, MO, USA), 10
ng/ml recombinant murine epidermal growth factor
(EGF) (Invitrogen)). At passage 6, MTECs were trans-
duced with either adenovirus b-galactosidase (adeno-b-
gal) or adeno-Cre at a multiplicity of infection (moi) of
80 plaque-forming units (pfu)/cell to generate WT and
KO MTECs, respectively. Adenoviral transduction was
repeated, and the deletion efficiency between WT and
KO MTECs was confirmed by both quantitative RT-
PCR (qRT-PCR) and Western blot analysis using the
reagents presented in Additional file 1 Tables S1 and
S2. After adenoviral transduction, MTECs were weaned
to medium containing only 2% FBS (DMEM/F-12 + 2%
FBS).
For subcultivation, cells were rinsed twice with Puck’s
A saline, then incubated for up to 60 minutes at 37°C in
a 3:1 solution of dispase II/0.25% trypsin reconstituted
in Puck’s A. No ethylenediaminetetraacetic acid (EDTA)
was utilized to subcultivate cells because treating cells
with trypsin-EDTA changed tumor cell morphology
from an epithelial (cuboidal) to a mesenchymal-like
(spindle) appearance. All cells were passaged less than
30 times before use in tumorsphere or in vivo assays.
Spent media were routinely tested for mycoplasma using
the MycoAlert Kit (Lonza, Basel, Switzerland).
All cells were grown either at normoxia in an air-
jacketed CO2 incubator (5% CO2; SANYO, Wood Dale,
IL, USA) or at hypoxia (0.5% O2, 5% CO2) in a multigas
incubator (SANYO) in which N2 gas displaces O2. Cells
were exposed acutely (≤6 hours) or chronically (> 6
hours to several days) to hypoxia and were removed
from chronic hypoxic exposure only for brief periods to
change the media.
For immunostaining of cultured cells, WT or KO cells
passaged with a dispase-trypsin mixture were plated into
tissue culture-treated chamber well slides (BD Bios-
ciences, Franklin Lakes, NJ, USA), grown to 60% to 80%
confluence and then postfixed for 20 minutes at room
temperature with 4% paraformaldehyde (PFA)-PBS, fol-
lowed by permeabilization with 0.5% Triton X-100 for 5
minutes. Cells stained with CD133 were not permeabi-
lized. Primary antibodies to CD133, Troma-I (K8), cyto-
keratin 14 (K14) and cytokeratin 5 (K5) were incubated
overnight at 4°C using the dilutions listed in Additional
file 1 Table S2. All cells were stained with 4’,6-diami-
dino-2-phenylindole (DAPI) prior to being mounted
with VECTASHIELD Mounting Medium (Vector
Laboratories, Burlingame, CA, USA).
Western blot analysis
Insoluble material remaining after preparation of whole-
cell extract (WCE) was reextracted in high-salt (HS)
solution (400 mM NaCl) buffer as described previously
[32], except that the deubiquitinase inhibitor N-ethylma-
leimide (NEM) was added to a final concentration of 0.5
μM. HS-WCE was resolved on 3% to 8% Tris-acetate
gels (1 to 10 μg/lane; Invitrogen) and transferred onto
polyvinylidene fluoride membranes prior to blocking
with 5% milk and enhanced chemiluminescence-based
detection of antibody complexes. All antibodies and
dilution factors are listed in Additional file 1 Table S2.
Gene expression
Total RNA was prepared using RNA-Bee RNA isolation
reagent (amsbio, Lake Forest, CA, USA), and RNA quality
was confirmed by the Agilent 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA, USA) assay. RNA with an
RNA integrity number > 9.0 was used to prepare cDNA
using the High-Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Foster City, CA, USA). qRT-PCR
was performed using optimized primer and 6-carboxy-
fluorescein-labeled probe sets designed using Universal
ProbeLibrary Assay Design Center software (Roche
Applied Science, Indianapolis, IN, USA) as described pre-
viously [33]. To control for cDNA input (40 to 80 ng/reac-
tion) when using cultured cells as the source of RNA, the
crossing point (Cp) values were normalized based on the
expression of the integrator complex subunit 3 (Ints3)
gene, which is expressed at moderate levels in the mam-
mary gland. This gene changes < 20% between WT and
KO cells cultured at normoxia or hypoxia and in WT and
KO tumors by Illumina whole-genome expression arrays
(Illumina Inc, San Diego, CA, USA) (TNS, personal obser-
vations). To compensate for any changes in epithelial con-
tent in whole tumors between genotypes, because only the
tumor epithelium is deleted for Hif1a, Ints3-normalized
Cp values were also normalized to Krt18 (cytokeratin 18).
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Cell growth and invasion assays
MTECs were grown in normoxic culture (ambient air;
5% CO2) or hypoxic culture (0.5% O2, 5% CO2) in med-
ium buffered with 25 mM 4-(2-hydroxyethyl)-1-piperazi-
neethanesulfonic acid (HEPES). On the day before
enumeration, either 350,000 cells/well in 6-well format
(complete growth medium) or 100,000 cells/well in 12-
well format (2% FBS medium) were seeded into multi-
well plates. In all cases, the medium was changed post-
plating, but was not replenished for the duration of the
experiment. Cells were harvested after culture for 0, 24,
48, 72 or 96 hours of culture at normoxia and hypoxia.
All cells were plated in triplicate or quadruplicate per
genotype/oxygen tension/time point. Each replicate was
counted by hemacytometer, and counts were verified
using an Accuri personal flow cytometer after gating
against cell debris (BD Biosciences).
For invasion assays, WT and KO MTECs that had
been gradually weaned to medium supplemented with
0.5% FBS were cultured overnight in serum-free
DMEM/F-12 medium. The next day 25,000 cells were
plated onto control inserts or Matrigel-coated transwell
inserts (BD Biosciences) and attractedto wells containing
complete growth medium with 5% FBS. Cells were pla-
ted in triplicate per genotype/oxygen tension. The mean
cell invasion index corrected for random migration was
calculated after 48 hours according to the manufac-
turer’s instructions. Changes in invasion are expressed
as a fold changes relative to the invasion index observed
for WT cells cultured at normoxia (fold change = 1.0).
Mammary tumor epithelial cell transplant into FVB
recipients
MTECs dissociated into single cells with 0.05% trypsin-
EDTA were counted using a hemacytometer and diluted
into HBSS. When transplanted into recipients at rela-
tively low density (≤500 cells/gland), cells were diluted
1:1 (vol:vol) with growth-factor reduced Matrigel-Hank’s
balanced salt solution (HBSS). At higher densities, cells
were resuspended in HBSS alone. Cells were kept on ice
until injection into the right inguinal mammary fat pads
(10 μl) of 3-week old female FVB/Nj recipients (The
Jackson Laboratory) using a 26-gauge PT2 needle
mounted on a Hamilton syringe, followed by clearing of
the endogenous epithelium. Recipients were palpated
one or two times per week, and outgrowths were mea-
sured with digital calipers to calculate tumor volume as
described previously [27].
Tissue histology and immunostaining
Tumors were harvested from anesthetized mice and
flash-frozen in liquid nitrogen for preparation of RNA
or protein, or they were fixed in 10% neutral buffered
formalin (NBF) for 6 hours at room temperature for
histological staining (H & E) and immunostaining. Par-
affin-embedded sections (5 to 7 μm) were immunos-
tained after antigen retrieval (1 × citrate buffer) using
the primary antibodies listed in Additional file 1 Table
S2, followed by development with a VECTASTAIN Elite
ABC Kit and ImmPACT DAB (diaminobenzidine) sub-
strate (Vector Laboratories). Alternatively, to prepare
frozen sections suitable for CD133, Troma I, K14 and
K5 immunofluorescent staining, anesthetized mice were
perfused intracardially with 10% NBF. Tumor tissue was
postfixed for 10 minutes in NBF at room temperature
prior to cryoprotection overnight at 4°C in 30% sucrose-
PBS, embedding in OCT medium and preparation of 10
μm sections by cryostat. Sections used for visualizing
the keratins were postfixed for an additional 10 minutes
in 10% NBF prior to 0.5% Triton X-100 permeabiliza-
tion. All antibodies and staining conditions are listed in
Additional file 1 Table S2.
Lung metastasis and survival studies
Lungs were either harvested from recipients at the same
time as primary tumors (at a volume of approximately
1,000 mm3), 8 weeks after primary tumor resection (500
to 750 mm3) or when recipients subjected to tumor
resection were moribund as indicated by body weight
loss > 15% and panting. Lungs were inflated with 10%
NBF and postfixed in NBF overnight. Paraffin-embedded
sections (7 μm) representing every 100 μm of lung tis-
sue were obtained for each paraffin block, and all sec-
tions were stained with H & E. The individual H & E-
stained section containing the highest number of metas-
tases per recipient, as evaluated by counting each slide
under a light microscope at × 50 original magnification,
was used to determine the grand mean of metastases
per genotype.
Tumorsphere culture and immunostaining
WT or KO MTECs were briefly trypsinized, washed and
strained (40 μm filter) to obtain single cells. The pre-
sence and viability of single cells were verified by view-
ing trypan blue-stained cells using a hemacytometer,
and only cells with > 90% viability were used in sphere
assays. Single cells were resuspended in serum-free
DMEM-F-12 mammosphere media containing 20 ng/ml
mouse recombinant EGF, 20 ng/ml basic fibroblast
growth factor, 1 × B27 (all from Invitrogen) and 4 μg/
ml heparin (Sigma-Aldrich, St Louis, MO, USA) as
described previously [34]. Primary tumorspheres were
derived by plating 30,000 single cells/well into six-well
ultra-low-adhesion dishes. Secondary and tertiary
tumorspheres were plated at 5,000 to 10,000 cells/well
and 2,000 cells/well, respectively. Dishes were cultivated
at normoxia or hypoxia (0.5% O2; 5% CO2) for 10 to 14
days prior to enumeration of spheres. Individual spheres
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≥ 100 μm from each replicate well (n ≥ 12 wells/geno-
type/oxygen tension) were counted under a dissecting
microscope. The percentage of cells capable of forming
spheres, termed the “sphere formation efficiency” (SFE),
was calculated as follows: [(number of spheres formed/
number of single cells plated) × 100]. End point tumor-
spheres were collected from ultra-low-adhesion dishes,
washed with PBS, then flash-frozen for preparation of
RNA or dried onto slides for 10 to 15 minutes at 37°C.
Slides were postfixed with 4% PFA-PBS for 15 minutes
and immunostained with the antibodies indicated in
Additional file 1 Table S2. All slides were stained with
DAPI prior to being mounted in either ProLong Gold
antifade reagent (Invitrogen) or VECTASHIELD Mount-
ing Medium (Vector Laboratories).
Tumor digestion and flow sorting
All mammary gland tumors used for flow-sorting
experiments were harvested from intact Hif1a DF,
MMTV-PyMT+ (equivalent to HIF-1a WT) transgenic
female mice at a size of > 300 mm3 but < 1,500 mm3.
Necrotic areas were removed from solid tumor tissue,
and solid tissue was cut into small fragments with scis-
sors. Tumor tissue was then weighed and chopped for 5
minutes with scalpels, followed by 5 minutes of chop-
ping to a fine paste with razor blades. The tissue paste
was digested in digestion buffer (DMEM/F-12, 1 × gen-
tamicin, 1 × antibiotic-antimycotic (Sigma-Aldrich), 300
U/ml collagenase type III (Worthington Biochemical
Corp) and 100 U/ml hyaluronidase (Sigma-Aldrich)) for
1 to 2 hours at 37°C at 125 rpm (10 ml/g tissue).
Digested tissue was pelleted by centrifugation, and the
red blood cells were lysed with a solution of 0.8%
NH4Cl-HBSS. To obtain single cells, organoids were
further digested with 0.25% trypsin-EDTA for up to 10
minutes at 37°C and washed with serum-containing
medium to inactivate trypsin, followed by a final diges-
tion for 10 minutes at 37°C in 5 mg/ml dispase II
(Roche Applied Science)/Puck’s A solution containing 1
mg/ml DNase I (Roche Applied Science). The cell sus-
pension was passed through a 40 μm filter insert, and
this flow-through was then passed through a flow cyt-
ometer tube with a 35 μm filter cap insert to further
enrich for single cells. Viability postdigestion was routi-
nely assessed by trypan blue staining. Only cells with
viability > 85% were subjected to antibody staining.
Isolated single cells were resuspended to a density of
up to 5 million cells/ml in flow buffer (HBSS, 2% FBS,
10 mM HEPES) and incubated for 1 hour on ice with
the biotin- or fluorophore-conjugated antibodies listed
in Additional file 1 Table S2. These antibodies included
a biotin-conjugated anti-mouse hematopoietic lineage
panel supplemented with anti-mouse CD31-biotin, anti-
mouse CD133-phycoerythrin (CD-133-PE) and anti-
mouse CD24-fluorescein isothiocyanate (CD24-FITC),
each at a 1:100 dilution. Secondary antibody incubation
(streptavidin-allophycocyanin) in flow buffer was per-
formed for 30 minutes on ice. After being stained, cells
were strained through a clean flow cytometer tube with
a 35 μm filter cap. To determine cell viability, either
SYTOX Blue (1 μM; Invitrogen) or 7-AAD (1 μg/ml;
BD Biosciences) was added to each flow tube sample 10
to 20 minutes before flow cytometry analysis.
Cells were subjected to cytometric profiling using a
100-μm nozzle at a sheath pressure of 20 psi on a BD
Biosciences FACSAria flow cytometer (maintained by
the University of Tennessee Health Science Center Flow
Cytometry and Sorting Core) equipped with violet (404
nm), blue (488 nm), green (532 nm) and red (635 nm)
lasers and applying FACSDiva software. All sample and
collection tubes were maintained on ice. BD Biosciences
CompBeads stained with either CD133-PE or CD24-
FITC were used to set the compensation gates, and cells
stained with isotype-matched secondary antibodies were
used as controls for staining specificity. Cells heat-killed
for 30 minutes at 65°C were used to gate against dead
cells positive for SYTOX Blue or 7-AAD. Lineage-nega-
tive (Linneg) cells were identified by gating against cells
positive for the mouse lineage panel + CD31. Because
almost 100% of cells isolated from late-stage carcinomas
of the PyMT-transgenic mouse were positive for CD24-
FITC as previously described [19], viable, Linneg mam-
mary tumor cells were gated in a two-way sort for
CD133hi versus CD133neg cells.
Sorted cell samples were collected directly on ice into
15 ml conical tubes precoated with 20% FBS, and a sub-
set of collected cells was subjected to postsorting analy-
sis to verify the purity and viability of the sorted
populations. Sorted cell populations were immediately
pelleted, washed to remove FBS and counted using a
hemacytometer prior to reconstitution in mammosphere
medium and plated in six-well ultra-low-adhesion dishes
(Corning Life Sciences, Corning, NY, USA) at the indi-
cated densities. FACSDiva plots were imported into
FlowJo version 7.0 software (Tree Star Inc, Ashland, OR,
USA) for data analysis and creation of histogram plots.
Limiting dilution transplantation
WT or KO MTECs were briefly trypsinized, washed
with HBSS and serially diluted into 1:1 HBSS/Matrigel.
Six dilutions per genotype (500, 200, 100, 50, 25 or 10
cells/10 μl) were introduced into the right inguinal
cleared fat pads of FVB/Nj recipients. Tumor-initiating
potential was defined as the ability to form a palpable
tumor mass > 5 mm diameter (approximately pea-
sized). The estimated TIC frequency was calculated
using Extreme Limiting Dilution Analysis (ELDA) soft-
ware [35]. Fisher’s exact (c2) test was used as a
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complementary approach to compare TIC activity
between WT and KO cells at each cell density evaluated
(GraphPad Prism version 4.0 software; GraphPad Soft-
ware, Inc, San Diego, CA, USA). All animals were pal-
pated twice weekly until surgical resection of the
primary tumor or euthanasia.
Image acquisition
Western blots were scanned at 600 dpi and imported
into Photoshop software (Adobe Systems, Inc, San Jose,
CA, USA). Digital images of immunostained or H & E-
stained tissue sections and cells cultured on chamber
well slides were captured using a Leica DM6000 upright
fluorescence microscope (Leica Microsystems, Inc, Buf-
falo Grove, IL, USA) mounted with a SPOT Insight
cooled charge-coupled device camera (SPOT Imaging
Solutions, Inc, Sterling Heights, MI, USA) and imported
into Photoshop using SimplePCI software (Hamamatsu
Photonics, Sewickley, PA, USA). All images between
genotypes and conditions per experiment were digitally
captured for the same exposure time. Immunostaining
images were not digitally altered to reduce background
or to adjust brightness or gain. Confocal images of
spheres were captured every 0.75 μm with a Zeiss
LSM210 microscope system (Carl Zeiss, Thornwood,
NY, USA). Appropriate gain and black level settings
were determined based on spheres incubated with sec-
ondary antibody alone. All images were captured using
the same gain and exposure settings, and upper and
lower thresholds were set using the range indicator
function. No additional background correction algo-
rithms were applied. Digital slices were merged into a
single, composite image using Zeiss Zen software.
Results
A mammary tumor model with constitutively deleted
Hif1a
We observed that HIF-1a expression generally increased
during tumor progression in MMTV-PyMT mice as
previously observed in patients [6], thereby confirming
that the MMTV-PyMT model is appropriate for these
studies (Additional file 2 Figure S1). To generate a par-
ental pool of MTECs, mammary tumors were isolated
from Hif1a floxed (DF), PyMT+ females (FVB/Nj back-
ground), and epithelial cells were transduced with ether
adeno-b-gal or adeno-Cre to create HIF-1a WT and
KO cell lines, respectively. Efficient Hif1a deletion was
confirmed by qRT-PCR and Western blot analysis
(Additional file 2 Figure S1).
During expansion, MTECs were weaned from com-
plete growth medium to medium supplemented only
with 2% FBS, as low-serum medium was previously uti-
lized to evaluate cell growth [27]. The levels of HIF-1a
detected by Western blot analysis following acute (0 to
6 hours) or prolonged (> 6 hours) hypoxia was deter-
mined using WT MTECs. On the initial day of hypoxia
exposure, cells were 80% confluent prior to transfer to a
hypoxic chamber for 24, 12, 8, 6 and 3 hours prior to
harvest. Cells taken from normoxic culture (labelled as
time t = 0) were harvested at the same time as cells that
had been exposed to hypoxic conditions for 24 hours.
Similar to the profile observed in Hep3B cells [36], HIF-
1a peaked by 3 hours of exposure to 0.5% O2, and, by
24 hours, expression had attenuated to basal levels (Fig-
ure 1A). This decrease in HIF-1a expression may be
due HIF-1a’s role in transcriptional regulation of the
prolyl hydroxylase enzymes, which mediate HIF-1a’s
turnover by the proteasome, thereby creating a negative
feedback loop [37].
In contrast, when WT cells were cultured in the pre-
sence of serum and EGF, HIF-1a levels were not attenu-
ated by prolonged hypoxia exposure (Additional file 2
Figure S2), and, in fact, HIF-1a stabilization at hypoxia
remained robust for at least 24 hours. Compared to the
levels of HIF-1a expression observed in cells cultured in
2% FBS alone, EGF treatment increased HIF-1a levels
approximately fourfold at normoxia (time t = 0), and
this upregulation increased to > 10- or > 20-fold follow-
ing 3 or 24 hours in hypoxic culture, respectively. The
effect was not due to the differences in serum or insulin
concentrations between culture media because WT cells
cultured in 5% FBS + 5 μg/ml insulin without EGF
expressed levels of HIF-1a similar to those of cells cul-
tured in 2% FBS alone (data not shown). Overall, these
results indicate that EGF is a potent regulator of HIF-1a
expression in normoxic PyMT mammary tumor cells, as
previously observed in SK-BR-3 and MCF-7 cells [38],
and that EGF prolongs HIF-1a stabilization under
hypoxic conditions.
HIF-1a promotes cell growth and invasion
To determine whether the HIF-1a KO PyMT+ MTECs
derived from ex vivo adenoviral transduction behave
similarly in vitro as previously described [27], cell growth
was compared in WT and KO cells cultured at normoxia
and hypoxia. Cell growth was also compared for WT and
KO cells cultured in complete or minimal (2% FBS only)
growth medium. By 48 hours of culture, and then
throughout the time course, there was a statistically sig-
nificant difference between WT and KO cell number at
normoxia and hypoxia for each medium formulation
(Figure 1B); overall, fewer KO than WT cells were
observed following exposure to either oxygen tension.
Cells cultured in complete growth medium grew faster
than those in reduced serum. In cells grown in 5% FBS +
EGF, more KO than WT cells were often observed by 96
hours of culture at normoxia (Figure 1B), owing to the
acidic environment of the superconfluent WT cells as
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Figure 1 Effect of Hif1a deletion upon growth and invasion. (A) Wild-type (WT) mammary tumor epithelial cells (MTECs) grown to 80%
confluence were subjected to hypoxic culture for the indicated times up to 24 hours, or cells continued to be cultured under normoxic
conditions such that the time t = 0 sample was harvested on the same day as the time t = 24 hours hypoxic condition sample. High-salt
enriched whole-cell extracts were resolved on 3% to 8% Tris-acetate gels and blotted onto polyvinylidene fluoride membrane, which was
divided horizontally at approximately 60 kDa. The top half of the blot was used to detect HIF-1a, and the lower portion was used to detect
lamin (loading control) to avoid the need to strip and reprobe the blot. (B) Growth curve of WT and knockout (KO) MTECs cultured at normoxia
(Nor) or hypoxia (Hyp) in growth medium supplemented with 5% fetal bovine serum (FBS) + epidermal growth factor (EGF) (left) or with 2% FBS
(right). For cells grown in 5% FBS + EGF, a representative graph is shown in which the mean ± SEM of cell number per time point of
quadruplicate wells per genotype/oxygen tension is plotted per time point. For cells grown in 2% FBS, the grand mean ± SEM of cell number is
presented, which was calculated as an average of the mean cell number observed per replicates per time point as observed in three replicate
experiments. All data were analyzed by two-way analysis of variance (ANOVA, *P < 0.05). (C) The mean fold change (FC) in invasion was
normalized to the invasion index observed for WT cells cultured at normoxia (FC = 1.0). Data represent the mean FC in invasion observed in
three independent experiments. All columns were compared using one-way ANOVA with a Bonferroni posttest. *P < 0.05.
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reported previously [39]. As expected, hypoxia exposure
decreased the rate of growth for both WT and KO cells,
although the difference between WT and KO cell density
was the most striking following extended hypoxia expo-
sure (≥ 72 hours).
Cells cultured in 2% FBS medium were gradually
weaned to reduced serum (0.5% FBS) prior to use in
invasion assays since immediate serum withdrawal
resulted in massive cell death even when cells had been
routinely cultured in medium containing 2% FBS. Dele-
tion of Hif1a reduced invasion at normoxia by 3.9-fold
and by 3.5-fold at hypoxia (Figure 1C). In contrast, sig-
nificant induction of invasion by WT cells during
hypoxia was not observed as previously described [27].
Although there was a trend toward increased invasion,
the differences were not significant on the basis of ana-
lysis of variance (ANOVA) analysis. Likewise, there was
no significant difference in the invasion potential of KO
cells between normoxic and hypoxic culture.
Expression of basal markers is reduced in cultured
knockout cells
The expression of markers of the luminal lineage
(Troma-I, detecting cytokeratin 8, K8) and the basal line-
age (cytokeratins 5 and 14, K5 and K14) by WT and KO
cells was evaluated by immunofluorescent staining of
nearly confluent cells that were cultured overnight (12 to
14 hours) at normoxia or hypoxia (Figure 2). The major-
ity of WT and KO MTECs cultured at normoxia (Figures
2a and 2e) and hypoxia (Figures 2i and 2m) stained with
antibodies to K8. This was expected because the PyMT
model is a luminal-like model of breast cancer. However,
fewer KO cells expressed K14 when cultured at either
normoxia (Figure 2b vs 2f) or hypoxia (Figure 2j vs 2n).
Hypoxic culture downregulated K14 expression in both
WT and KO cells (Figure 2b vs 2j and Figure 2f vs 2n).
Overall, fewer KO cells were dual-positive for K8 and
K14 (yellow cells), suggesting a reduction in a bipotent

















Figure 2 Loss of basal marker expression in cultured HIF-1 knockout cells. Wild-type (WT) or knockout (KO) cells were plated onto tissue-
culture-treated slides and grown to subconfluence, at which time subsets of cells were exposed overnight to hypoxic (Hyp) culture or remained
under normoxic (Nor) culture. Cells were costained with Troma-I (K8, green) and K14 (red) (a) to (c), (e) to (g), (i) to (k) and (m) to (o) or with
K5 alone (d), (h), (l) and (p); images showing either the green (K8) or red (K14) channel from the co-stained slides are also presented (a) to (b),
(e) to (f), (i) to (j) and (m) to (n). All slides were counterstained with 4’,6-diamidino-2-phenylindole (DAPI). Images were captured at ×200
original magnification (scale bar = 50 μm).
Schwab et al. Breast Cancer Research 2012, 14:R6
http://breast-cancer-research.com/content/14/1/R6
Page 8 of 25
deletion. The most striking phenotype was that no K5+
cells could be detected in KO cells cultured at either nor-
moxia (Figure 2d vs 2h) or hypoxia (Figure 2l vs 2p).
Hypoxic induction of K5 mRNA has previously been
reported in MCF-7 cells, [40]; however, an increase in
the number of K5+ cells was not apparent in PyMT WT
cells exposed to hypoxia (Figure 2d vs 2l).
Primary mammary tumor growth is HIF-1a-dependent
To evaluate the contribution of HIF-1a to primary tumor
growth in a syngeneic transplant approach, WT or KO
MTECs (n = 50,000) were injected into single, cleared
inguinal mammary fat pads of FVB/Nj recipient females.
Single-side injections were utilized to prevent one tumor
from influencing the outgrowth of a contralateral tumor.
There was an approximately 60% decrease in the wet
weight and volume of KO tumors at week 8 posttrans-
plant, when recipients bearing WT tumors required
euthanasia in compliance with institutional maximum
tumor size recommendations (Figure 3A). Moreover, the
rate of KO tumor growth was slower over the entire
course of tumor development (Figure 3B). When fewer
WT or KO cells were utilized to generate mammary
tumors (500 cells/gland), there was a more pronounced
delay in the ability of KO cells to form a tumor with a
volume > 500 mm3 (Figure 3C). The median time to
form large tumors increased from 64 days for WT cells
to 127 days for KO cells (Figure 3C).
To confirm that end point KO tumors did not express
HIF-1a, Western blotting was performed using extracts
isolated from three randomly selected whole WT or KO
tumors. Very low levels of HIF-1a were detected in KO
end-stage tumors (Figure 3D). Residual expression was
likely observed because of the presence of stromal compo-
nents derived from the host recipients, such as tumor-
associated macrophages. As expected, the expression of
three classic HIF-1 target genes, vascular endothelial
growth factor (Vegf), phosphoglycerate kinase 1 (Pgk1) and
glucose transporter 1 (Slc2A1 or Glut1), was reduced in
KO tumors (Figure 3E). However, the gross histopathology
of tumors was not affected by deletion of Hif1a; all tumors
were poorly differentiated, solid adenocarcinomas as pre-
viously described in the PyMT-transgenic mouse [25]
(Additional file 2 Figure S3).
Because WT tumors were larger than KO tumors, they
also exhibited more extensive necrosis than KO tumors.
High-resolution, digitally scanned whole slides of H & E-
stained tumors may be viewed using a link to a public
database (refer to the Additional material). Because a lar-
ger percentage of KO tumor cells were viable, it is not
surprising that more Ki67 and caspase 3-positive cells in
KO tumors were detected by immunostaining (Figure 3F
and Additional 2, Figure S4). Overall, these changes
would be expected to have a zero net effect on KO tumor
growth. In addition, as previously reported for late-stage
PyMT carcinomas [25], tumors derived from trans-
planted WT or KO cells did not exhibit any cells positive
for ERa by immunostaining (Additional file 2 Figure S5).
HIF-1a promotes an epithelial-to-mesenchymal transition
phenotype and regulates K5 expression in vivo
To determine whether the expression of K5 and K14 was
reduced in KO tumors as in cultured cells, expression of
K8, K14 and K5 was also evaluated by immunofluorescent
staining of end-stage tumors harvested from FVB recipi-
ents bearing WT or KO tumors (four tumors/cohort). The
immunostaining pattern was compared to that observed in
tumors harvested from intact PyMT-transgenic mice. In
contrast to results obtained in cultured cells, very few cells
were dual-positive for K8 and K14 in WT tumors.
Furthermore, no cells positive for K5 or K14 were detected
in any KO tumors (Figure 4A) (four tumors/genotype). In
contrast, there were no obvious changes in the expression
or localization of p63 detected by colorimetric immunos-
taining of paraffin-embedded sections (Additional file 2
Figure S5; refer also to supplementary database of digitally
scanned whole slides).
qRT-PCR analysis of RNA prepared from the same
tumors for which sections were prepared for immunos-
taining revealed that Krt14 (K14) and Krt5 (K5) mRNA
levels were reduced in KO tumors by 3.8- and 2.0-fold,
respectively. As expected based on the ability of hypoxia
to promote an epithelial-to-mesenchymal transition
(EMT) phenotype through the Notch pathway [41], mul-
tiple core genes in the EMT signature were downregu-
lated in KO tumors compared to WT tumors, including
Snail, Slug, Twist1 and Fn1 (fibronectin), whereas
expression of Krt18 (K18) was not affected by HIF-1a
deletion (Figure 4B).
Constitutive Hif1a deletion represses metastasis and
prolongs survival
Initially, metastasis was evaluated in WT or KO tumor
recipients by harvesting lungs on the same day as the pri-
mary tumors. Because recipients bore a single tumor, in
contrast to the transgenic model, in which all ten mam-
mary glands become tumor-laden, very few metastases
were present. The lungs from WT hosts exhibited a
mean of two micrometastases, and the majority of lungs
from KO hosts were devoid of metastases (Figure 5A).
One caveat with regard to interpreting these data is
that the tumors developed by the KO cells were 60%
smaller than the WT (Figure 5B). Therefore, to compare
the effect on lung metastasis when WT and KO tumor
volumes were equivalent, the primary tumor was resected
during a survival surgical procedure when tumors were at
least 1.5 cm in diameter with a corresponding volume
range of 500 to 750 mm3. Animals subjected to survival
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Figure 3 Deletion of Hif1a decreases primary tumor growth. (A) Wild-type (WT) or knockout (KO) cells (n = 50,000) were transplanted into
FVB/Nj mice. All tumors were harvested at day 56 to evaluate tumor weight, volume and burden (percentage tumor weight/total body weight,
BW) (n = 10 recipients/genotype, P < 0.05, unpaired Student’s t-test). (B) The growth rate of WT and KO tumors following transplant of 50,000
cells. Best-fit curves were established based on a polynomial fit algorithm using GraphPad Prism 4.0 software. Data in (A) and (B) are
representative of seven independent experiments (> 60 recipients/genotype). (C) When 500 WT and KO cells were implanted into the mammary
fat pad, the median time until 50% of recipients developed tumors > 500 mm3 was 64 days for WT mice and 127 days for KO mice (n = 14
recipients/genotype, P < 0.001, logrank test). (D) Western blot for HIF-1a in three independent tumors (500 to 750 mm3) per genotype. WT and
KO cells that were cultured for 6 hours under hypoxic conditions served as positive and negative controls, respectively. CRM, cross-reactive
material. MTEC, mammary tumor epithelial cell. (E) Mean fold change ± SEM in expression of HIF-1 targets in KO tumors as determined by qRT-
PCR (n = 5 tumors/genotype). Decreased gene expression in KO tumors is presented as a negative fold-change relative to WT tumors. (F) An
increase in Ki67+ cells in KO tumors is balanced by an increase in caspase 3-positive cells (n = 5 tumors/genotype, *P < 0.05, Student’s t-test).
Representative immunostaining images are shown in Additional file 2 Figure S4.
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surgery to resect the primary tumor were divided into
two cohorts. In the first cohort, females were euthanized
8 weeks postsurgery. WT tumor cells developed large
macrometastases visible to the naked eye, as well as sev-
eral micrometastases visible by microscopic analysis, with
a mean of 19 metastases per lung (Figures 5B and 5C). In
contrast, lungs from KO tumor recipients contained 50%
fewer metastases (Figures 5B and 5C), which were also
smaller overall than the WT metastases. Furthermore,
50% of host mice transplanted with WT cells were
deemed moribund and required euthanasia prior to the
8-week postsurgical period, whereas all hosts harboring
A
B
50 μm 50 μm50 μm



















K18 Snail Slug Twist1 Fn1 K14 K5
Figure 4 Loss of cells expressing K14 or K5 in HIF-1a knockout tumors is accompanied by a reduction in the expression of markers of
the epithelial-to-mesenchymal transition. (A) Frozen sections were prepared from tumors harvested from PyMT+ transgenic mice or from
wild-type (WT) and knockout (KO) tumors harvested from FVB recipients. All tumors were ≥ 500 mm3 in volume. Sections were costained with
antibodies to K14 (red) and K8 (green) or K5 (red) alone and counterstained with DAPI. Images were captured at ×200 original magnification.
Scale bar = 50 μm. (B) The mean fold change ± SEM in gene expression observed in end-stage KO tumors of Krt14 (K14) and Krt5 (K5) mRNAs,
as well as multiple markers of the epithelial-to-mesenchymal transition, as determined by qRT-PCR performed using the primers and probes
listed in Additional file 1 Table S2 (n = 5 tumors/genotype). The mean ± SEM of biological replicates is graphed. The expression of Snail, Slug,
Twist1, Fn1, Krt14 (K14) and Krt5 (K5) mRNAs was reduced in KO tumors compared to WT tumors; however, the expression of Krt18 (K18) varied
by < 20% between genotypes.
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KO cells lived the full 8 weeks. Therefore, although KO
MTECs retain the capacity to complete the full meta-
static program, metastasis is significantly suppressed.
In the second cohort subjected to the tumor resec-
tion paradigm, recipients were allowed to survive until
moribund due to lung metastases (Figure 5D). Recipi-
ents bearing WT tumors succumbed to lung metas-
tases sooner than KO recipients did (Figure 5D). The
median survival increased from 66.5 days for WT reci-
pients to 88 days for KO recipients (14 WT and 21
KO; logrank score, P < 0.001). Furthermore, about 25%
of mice implanted with KO tumors (5 of 21) lived
longer than 1 year and did not develop any lung
metastases as evaluated by H & E staining of sections
from their lungs.
Deletion of Hif1a decreases tumorsphere formation
To begin to determine whether HIF-1a may play a role
in regulating breast cancer stem cell activity, single WT
or KO cells were placed into tumorsphere culture. All
data shown in Figure 6 are representative of experi-
ments with several biological replicates. A summary of
the fold changes in SFE (the number of cells capable of
forming spheres/total number of cells plated × 100)
among biological replicate experiments is presented in
Additional file 2 Figure S6. As shown in Figure 6A, the
mean SFE decreased 4.1-fold in the primary, 2.2-fold in
the secondary and 2.5-fold in the tertiary generations of
spheres derived from KO cells, respectively. The mean
SFE among biological replicate experiments varied from
0.06% to 1.55% for WT cells and from 0.015% to 0.85%
for KO cells. Variability in the sphere assay among bio-
logical replicates by more than a log10 factor is not unu-
sual [42]. More importantly, SFE within each
experiment was always greater for WT cells than for
KO cells.
As shown in Additional file 2 Figure S6, the mean fold
enrichment in SFE in WT cells was 4.3-fold for the pri-
mary generation (range 2.85- to 7.23-fold), 4.1-fold for
the secondary generation (range 1.85- to 6.7-fold) and
2.61-fold for the tertiary generation (range 2.1- to 2.79-
fold). In each case, the mean fold change was deter-
mined on the basis of at least three biological replicates/
genotype/generation. Because the WT and KO cells had
previously been cultivated in monolayer in the presence
of serum, the ability of HIF-1a to promote SFE was
confirmed using tumor cells derived from freshly
digested Hif1a DF, PyMT+ tumors originating in intact
transgenic mice.
Following isolation from freshly digested tumors, sin-
gle cells were immediately exposed in suspension to
adeno-b-gal or adeno-Cre (moi of 80, for 2 to 3 hours),
washed to remove viral particles and then plated at
equal density into sphere culture conditions. Spheres
derived from the primary generation were digested with
trypsin, reexposed to adeno-b-gal or adeno-Cre in
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Figure 5 HIF-1a expression in tumor epithelium is required for metastasis. (A) Mean number of micrometastases ± SEM observed when
lungs were harvested at the same time as the primary tumors (> 1,000 mm3) (n = 9 wild-type (WT) and 14 knockout (KO) recipients, *P < 0.05,
unpaired Student’s t-test). (B) Enhancement of lung metastases when WT and KO primary tumors were surgically resected at equivalent volumes
(500 to 750 mm3), followed by 8 weeks of survival (n = 32 WT and 22 KO recipients, *P < 0.05, Student’s t-test). (C) Representative images of
lungs harvested from WT or KO mammary tumor epithelial cell recipients 8 weeks after tumor resection (original magnification, ×50). (D) The
impact of HIF-1a expression in tumor cells on the survival of recipients following tumor resection. A subset of animals subjected to primary
tumor resection was allowed to survive until moribund due to metastasis. The morbidity hazard ratio was 3.78 times higher when hosts bore WT
tumors (n = 14 WT and 15 KO hosts, logrank test, P = 0.00039, 95% CI = 1.53 to 9.31).
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suspension (80 moi for 2 to 3 hours) and plated for sec-
ond-generation spheres. Deletion efficiency was deter-
mined for each generation by qRT-PCR of genomic
DNA isolated from a fraction of cells collected at 72
hours postplating, prior to the formation of large
tumorspheres.
In contrast to the established KO MTECs, not all
floxed cells exposed 2-3h to adeno-Cre were deleted for
Hif1a. A mean deletion efficiency of 71% or 84% was
observed following the first or second round of trans-
duction with adeno-Cre, respectively. Despite incom-
plete Hif1a deletion primary and secondary SFE was
reduced in Hif1a-deleted cells by 2.53-fold and 2.30-fold
at the primary and secondary generations, respectively
(Figure 6B). The mean fold change in SFE between WT
and Hif1a deleted (KO) cells among three biological
replicates of this assay was 5.74-fold for the primary
generation (range of 2.53-8.2- fold) and 4.38-fold for the
secondary generation (range of 2.30-6.54-fold) (Addi-
tional file 2 Figure S6). These results confirm that the
enrichment in SFE observed for WT cells previously
cultured in monolayer with FBS was not an artifact due
to culture conditions, and suggested that HIF-1a may
promote breast TIC potential in vivo.
Sphere formation was also assayed after culture of WT
and KO cells at normoxia or chronic hypoxia. Figure 6C
presents data from one experiment in which there was a
2.28-fold reduction in KO SFE at normoxia and a 2.1-fold
reduction in KO SFE at hypoxia, as compared to WT cells.
Among biological replicates the mean fold reduction in
KO SFE at normoxia was 3.26-fold (range of 2.20-6.15-
fold) and 6.85-fold at hypoxia (range of 2.1 to 9.17-fold)
(Additional file 2 Figure S6). Although there was a trend
towards hypoxia increasing WT SFE (mean fold increase
in SFE of 1.38, and a range of 1.17- to 1.70-fold, Additional
file 2 Figure S6), the increase was not statistically signifi-
cant in any independent experiment by ANOVA. Changes
in KO SFE between normoxia and hypoxia were also not
significant (mean fold change of 0.94, and a range of 0.35-
2.05-fold).
To determine if HIF-1a expression varied in spheres
cultured acutely or chronically at hypoxia, HIF-1a expres-
sion was evaluated by western blotting of HS-WCE pre-
pared from WT or KO spheres exposed to prolonged
hypoxia (≥ 4 days), or from WT or KO spheres that were
initially grown in normoxic culture, but were then briefly
exposed acutely to hypoxia (6 h) prior to harvest (Addi-
tional file 2 Figure S7). In sphere culture conditions, HIF-
1a was barely detectable in WT cells exposed to chronic
hypoxia, whereas robust expression of HIF-1a was
observed in WT cells exposed acutely to hypoxia. There-
fore, in contrast to data obtained from monolayer cultured
cells, EGF was not sufficient to stabilize HIF-1a expression
when cells are grown constitutively at hypoxia in sphere
culture.
One caveat of the tumorsphere assay is that spheres
may be derived from aggregation of single cells, or even
fusions of small spheres. The contribution of cell aggre-
gation to sphere formation was not directly assessed in
these experiments. However, the impact of aggregation
on overall WT and KO SFE is presumed to be minimal
since similar fold-changes in SFE between WT and KO
cells were observed when cells were plated in sphere
medium supplemented with 0.5% methylcellulose (data
not shown), which acts as a physical barrier to impede
cellular aggregation.
HIF-1a-dependent regulation of CD133 and the Notch
pathway
Since CD133, Notch receptors and Notch target genes
may each be modulated by the HIF transcription factors
[16,43,44], the expression of CD133, genes in the Notch
pathway and classic HIF targets were evaluated in WT
and KO tumorspheres by qRT-PCR. Figure 6D presents
the mean fold reduction in gene expression observed in
KO tumorspheres. Only genes that were consistently
observed to be downregulated across three biological
replicate experiments are shown. Expression of Notch4
was downregulated an average of 7.24-fold, whereas
expression of the Notch receptors Notch1, Notch2 and
Notch3 did not vary by more than twofold. The Notch
ligand Delta-like-1 (Dll1I) was also downregulated in KO
spheres an average of 9.73-fold, and the transcription fac-
tors Hey1 and Hey2 were downregulated 3.95-fold and
1.9-fold, respectively. The HEY family of genes has been
proposed to function as surrogate markers of Notch
activity in multiple human breast cancer cell lines [45,46].
Although the expression of the Jagged ligands has been
reported to be hypoxia-inducible in breast cancer cell lines
[45,46], we were unable to confirm a consistent effect of
HIF-1a on the expression of either Jagged1 or Jagged2 by
tumorspheres. For example, the expression of Jagged1 was
upregulated 3.0-fold in two experiments and downregu-
lated 3.0-fold in a third experiment, whereas the expres-
sion of Jagged2 was observed to be upregulated between
3- to 10-fold in two experiments and downregulated 3.0-
fold in a third experiment (data not shown). In addition,
the expression of Dll4, Hes1, Hes2 or Vegf, which is a
known direct HIF target gene, did not vary between WT
and KO spheres by more than 1.5-fold. The most striking
difference in gene expression was observed for Prom1
(CD133), which was consistently downregulated > 9.0-fold
in KO spheres (Figure 6D).
On the basis of the qRT-PCR results, the expression
of CD133 was then evaluated by immunostaining mono-
layer-cultured WT and KO MTECs grown at normoxia
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Figure 6 HIF-1a promotes tumorsphere formation in cultured cells and in freshly isolated tumor cells independent of oxygen tension.
(A) Representative experiment in which the mean sphere formation efficiency (SFE) ± SEM was determined when wild-type (WT) and knockout
(KO) cells were cultured in tumorsphere culture conditions. Tumorspheres ≥ 100 μm were scored positive, and the mean SFE (the percentage of
cells capable of forming spheres per total number of single cells plated) per experiment (n ≥ 12 wells/genotype, P < 0.05, unpaired Student’s t-
test) was determined at each of the primary, secondary and tertiary generations of spheres. A summary presenting the mean fold enrichment in
WT SFE observed among biological replicates is included in Additional file 2 Figure S6. (B) A representative experiment in which the mean
primary and secondary SFE ± SEM was determined when single cells were isolated from mammary tumors of Hif1a DF, MMTV-PyMT+ mice,
followed by immediate adenoviral transduction (n ≥ 12 wells/genotype, P < 0.05, unpaired Student’s t-test). (C) Comparison of SFE when WT or
KO cultured cells were subjected to normoxia or chronic hypoxia. Immediately following plating of single cells, dishes were cultured under
normoxic or hypoxic conditions for the duration of the experiment; therefore, cells were exposed to chronic hypoxia. The graph presents mean
SFE obtained from the secondary generation of spheres (n ≥ 12 wells/genotype). Differences among columns were assessed by one-way
ANOVA, *P < 0.05. (D) The mean fold change in gene expression observed in KO tumorspheres was evaluated by qRT-PCR. The grand mean fold
change ± SEM was determined on the basis of three independent experiments. cDNA was derived from three preparations of WT and KO
secondary spheres grown in six-well format and pooled at the experiment end point to prepare total RNA (n = 3 pools of spheres/genotype).
The mean expression of Notch 4 (N4), Dll1, Hey1, Hey2 and Prom1 (CD133) was reduced in KO tumorspheres by > 1.5-fold, whereas the mean
expression of Notch1, Notch2 and Notch3 (N1 to N3) or Vegf did not vary by > 50% between genotypes. The decreased expression in KO
tumorspheres is indicated as a negative fold change.
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or hypoxia (Figure 7A). Compared to WT cells, CD133-
positive cells were not readily detectable by immunos-
taining of KO cells following culture at normoxia or
hypoxia (Figure 7A). These results were validated by
flow cytometry following staining of WT and KO cells
cultured at normoxia with CD133-PE antibodies. As
shown in Figure 7B, the expression of CD133 was
reduced in KO cells more than 9.0-fold. CD133 expres-
sion was also compared by immunostaining tumor-
spheres derived from WT and KO cells that were grown
constitutively at normoxia (Figure 7C). As in cultured
cells, the expression of CD133 was increased in WT
spheres relative to KO spheres (Figure 7C), although in
contrast to monolayer culture, CD133-positive cells
were observed in KO spheres. Culture conditions influ-
enced the expression of CD133 mRNA levels because
expression increased by a mean of 5-fold in WT cells
spheres relative to the same passage of WT cells cul-
tured in monolayer in 2% FBS (data not shown).
To test whether CD133 expression influences SFE,
spheres were derived from the CD133hi or CD133neg
subpopulations of late-stage carcinomas arising in
PyMT+ transgenic females. Live Linneg single cells were
studied by flow cytometry after being stained with
CD133-PE. Among replicate experiments, the tumor
epithelial cells identified as highly positive for CD133-
PE ranged from 5% to 12%. A representative histogram
is presented in Figure 7D, showing that 5.99% of cells
were isolated as the CD133hi fraction. An example of
the gating strategy applied to sorting experiments is out-
lined in Additional file 2 Figure S8. The mean increase
in SFE in the CD133hi subpopulation compared to the
CD133neg fraction among replicate experiments was >
4.0-fold (a representative experiment is shown in Figure
7E), suggesting that CD133 may be a useful cell surface
marker to enrich for TICs in the PyMT model.
HIF-1a promotes tumor-initiating cell frequency in vivo
On the basis of the dramatic differences in growth rates
of WT and KO tumors and the reduction in SFE by
HIF-1a-KO cells in tumorsphere assays, the ability of
WT and KO cells to form tumors in recipients under
limiting dilution transplantation conditions was evalu-
ated. To permit estimation of TIC frequency due exclu-
sively to loss of HIF-1a activity, TIC potential was
compared using unsorted WT or KO MTECs to avoid
the physical stress encountered during sorting that
reduces cell viability and therefore affects the calculation
of TIC frequency [20]. The ability of WT or KO
MTECs to form a palpable tumor mass > 5 mm was
evaluated using a broad range of cell dilutions (10 to
500 cells: 10, 25, 50, 100, 200 and 500) (Table 1).
At each cell density evaluated, there was a statistically
significant enrichment in TIC activity in WT cells,
which was indicated by the percentage of FVB/Nj recipi-
ents positive for a palpable tumor (Figure 8A and Table
1). ELDA analysis [35] revealed a 35-fold reduction in
TIC frequency from KO to WT cells at day 36 post-
transplant (Table 1). Data were also statistically signifi-
cant on the basis of the Fisher’s exact test (Table 1).
The difference in TIC potential remained statistically
significant at day 62 posttransplant (Additional file 2
Figure S9, and Additional file 1 Table S3), with a 7.5-
fold enrichment in TIC frequency in WT cells. One rea-
son for the apparent decrease in the fold enrichment of
TIC frequency at day 62 may be that the data from the
500- and 200-cell recipients were excluded from the
ELDA analysis. All recipients in these two cohorts were
euthanized at day 36 (Additional file 2 Figure S10) to
compare the histological and gene expression profiles of
early-stage lesions. Notably, WT recipients in the 50-
and 100-cell input cohorts required surgical intervention
or euthanasia based on tumor volume by day 62 (Addi-
tional file 2 Figures S11 and S12), whereas no interven-
tion was required for KO recipients until day 96
posttransplant.
The mean volume of KO tumors derived under limiting
dilution conditions was reduced, and this difference was
maintained over several months. None of the KO tumors
derived from transplantation of 50 or fewer cells
exceeded a volume of 100 mm3 by day 62 (Figure 8B). By
day 112 posttransplant, 96% of recipients that received 10
WT cells had developed measurable tumors, whereas
55% of recipients that received 10 KO cells had not
(Additional file 1 Table S4). The mean tumor volume
among the tumor-positive 10-cell KO recipients was <
250 mm3 (Additional file 2 Figure S12). Supplementary
information summarizing the mean tumor volume per
cohort and the percentage of recipients with measurable
tumors at day 112 or 244 is presented in Additional file 1
Tables S4 to S7, and in Additional file 2 Figures S11 and
S12. The difference in TIC potential in the 10-cell cohort
remained significant until day 244 (Additional file 1
Table S7), when all animals were euthanized.
HIF-1a-dependent changes in gene expression were
evaluated in early-stage WT and KO masses (75 to 200
mm3; five tumors per genotype). Similar to results
obtained from spheres, Notch4, Hey1 and Hey2 mRNA
levels were decreased in KO tumors 2.25-, 4.27- and
2.3-fold, respectively (Figure 8C), whereas Notch1-
Notch3 mRNA levels decreased by less than 50%. All
other genes in the Notch pathway that were previously
found to be differentially expressed in spheres were
not differentially expressed among WT and KO
tumors, except for Vegf, which was downregulated by a
mean of 7.3-fold. As observed in end-stage tumors,
WT and KO Glut-1 and Pgk-1 mRNA levels were
reduced in tumors < 200 mm3.
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Figure 7 CD133 expression in PyMT mammary tumor epithelial cells is regulated by HIF-1a. (A) Subconfluent wild-type (WT) or knockout
(KO) cultured cells were exposed to acute hypoxia (Hyp) (6 hours), then immunostained for CD133 (green) and counterstained with DAPI.
Images were captured at ×200 original magnification. Scale bar = 50 μm. (B) Representative CD133-phycoerythrin (CD133-PE) staining profiles of
WT (red histogram) and KO (blue histogram) cells cultured at normoxia (Nor) and subjected to fluorescence-activated cell sorting analysis. The
isotype-only antibody control is also plotted (green histogram). The percentage of cells that were CD133-positive was determined on the basis
of the live, singlet, hematopoietic lineage panel-negative (Linneg) parent population using the FlowJo data analysis software package. (C)
Secondary WT or KO tumorspheres cultured at normoxia were harvested at the study end point from ultralow adhesion wells, dried onto glass
slides, stained with CD133-PE, counterstained with DAPI and imaged by confocal microscopy. The highlighted area (white boxes) shows a
higher-magnification image, which demonstrates that CD133 is localized to the cell surface. (D) Histogram of CD133-PE (red) in the live, singlet,
Linneg parent population of cells isolated from tumors that arose in the PyMT transgenic mouse as compared to the isotype antibody control
(green). Approximately 6% of cells were defined in this experiment as CD133hi. (E) A representative experiment showing the mean sphere
formation efficiency (SFE)/well ± SEM of CD133hi versus CD133neg subpopulations that were isolated by flow sorting and cultured at normoxia at
a density of 10,000 cells/well in six-well format (n ≥ 8 wells/genotype, unpaired Student’s t-test). The SFE was determined as the percentage of
cells capable of forming spheres per the total number of single cells plated.
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No gross changes in WT or KO tumor histopathology
were observed in recipients transplanted with 500 tumor
cells. None of the KO masses within this cohort were
detectable by manual palpation, but microscopic analysis
of H & E-stained sections revealed lesions < 5 mm in
five of eight recipients. Since Vegf mRNA was differen-
tially expressed, microvessel density was evaluated by
Chalkley scoring of sections immunostained with anti-
CD34 antibodies. Decreased Vegf mRNA levels corre-
sponded with a concomitant decrease in mean Chalkley
score in KO tumors (Figure 8D). In summary, deletion
of Hif1a reduced TIC potential as well as
neoangiogenesis.
Discussion
Although the role of hypoxia and the HIF-1a transcrip-
tional response in promoting tumor progression and
metastasis is well-established, the direct contribution of
the HIF family to the regulation of TICs in breast cancer
is unknown. HIF-1a rather than HIF-2a is the predomi-
nant regulator of the hypoxic response in breast cancer
[47]; therefore, we sought to determine the effect of Hif1a
deletion in the MMTV-PyMT model of breast cancer. In
this study, by using an ex vivo genetic deletion approach,
we generated constitutive HIF-1a-KO and control (WT)
MTECs isolated from a pool of MMTV-PyMT tumors.
One distinct advantage of this approach is that the
MTECs are transplantable to immunocompetent hosts,
preserving any host-derived effects on TIC potential fol-
lowing limiting dilution transplantation, in contrast to the
xenograft of human cells into immunocompromised mice.
Herein we show for the first time that HIF-1a positively
regulates TIC activity in breast cancer as suggested by
sphere formation assays in vitro and validated through
limiting dilution transplantation of WT and KO cells.
Additional advantages of the exogenous transduction
and transplantation approach versus crosses to MMTV-
Cre-transgenic mice include avoiding the mosaic nature
of MMTV-Cre expression, because not all epithelial
cells harboring floxed alleles of Hif1a undergo recombi-
nation [48], and avoiding the use of a mixed genetic
strain background by utilizing mouse models back-
crossed to a single strain (FVB/Nj). Because Hif1a dele-
tion impairs cell proliferation [39], an effect we also
observed in cultured KO MTECs (Figure 1B), incom-
plete recombination could permit nontargeted cells to
outgrow the recombined (KO) cells. Additionally, it had
not previously been assayed whether the lung metastases
originating in the MMTV-Cre-derived conditional KO
females were derived from the recombined tumor cells
or were generated from cells that had escaped recombi-
nation [27]. In addition, the prior use of a mixed strain
background may have introduced genetic modifier
effects that could influence tumor incidence and lung
metastasis. In particular, both tumor burden and lung
metastasis in the MMTV-PyMT model are enhanced on
the FVB/N background as compared to C57BL/6 [49].
In agreement with the findings of previous studies, our
study results confirm that HIF-1a promotes the growth
of MTECs cultured at hypoxia and enhances lung
metastasis in vivo [27]. However, there were some differ-
ences observed between the two model systems. For
example, we found that deletion of Hif1a repressed the
growth of cells at normoxia as well as at hypoxia (by 48
hours of culture). In addition, the magnitude of the
decrease in KO cell invasion was similar, regardless of
whether cells were cultured at normoxia or hypoxia,
whereas Liao et al. reported a difference only at hypoxia
[27]. No statistically significant increase in invasion
potential between WT cells cultured at normoxia and
Table 1 Estimation of tumor-initiating cell frequency of hypoxia-inducible factor-1a wild-type and knockout mammary
tumor epithelial cellsa
MTEC genotype




HIF-1a WT HIF-1a-KO P
valuesb
Number of cells injected, % (n)
500 78% (7 of 9) 0% (0 of 8) 0.0023
200 90% (9 of 10) 10% (1 of 10) 0.0011
100 77% (10 of 13) 9% (1 of 11) 0.0003
50 69% (11 of 16) 6% (1 of 16) 0.0006
25 30% (6 of 20) 0% (0 of 20) 0.0202
10 35% (8 of 23) 0% (0 of 22) 0.0038
Estimated TIC frequency by ELDA
(95% CI)
1 of 82 (1 of 57 to 1
of 117)
1 of 2,915 (1 of 925 to 1 of
9,193)
5.79e-21
aELDA, Extreme Limiting Dilution Analysis; HIF-1a, hypoxia-inducible factor 1a; KO, knockout; MTEC, mammary tumor epithelial cell; TIC, tumor-infiltrating cell;
WT, wild type. Frequency of tumors following limiting dilution transplantation of WT or KO MTECs is shown. The number of tumor-positive recipients per the
total number of recipients at day 36 posttransplant and the P-values between genotypes for each cell density tested are listed. The estimated frequency of TICs
was determined using the publicly available ELDA software. bP values were calculated using Fisher’s exact test.
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Figure 8 HIF-1a regulates tumor initiation potential in vivo. (A) Evaluation of the percentage of recipients (number of recipients positive for
a palpable mass per number of recipients successfully transplanted × 100) that developed a tumor mass by day 36 postinjection of unsorted
wild-type (WT) and knockout (KO) tumor cells. The asterisks indicate a significant difference between genotypes for a given cell density by
Fisher’s exact test. (B) Comparison of WT and KO mean tumor volumes ± SEM over time when 10, 25 or 50 cells were injected into the
mammary fat pads. (C) The mean fold change ± SEM in gene expression profiles of early-stage tumor masses was evaluated by qRT-PCR. All
genes displayed were downregulated in KO tumors as compared to WT tumors (n = 4 tumors/genotype/experiment).
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hypoxia was observed, as reported previously [27]. In
contrast to observations from either PyMT model sys-
tem in which Hif1a was deleted, short hairpin RNA-
mediated knockdown of HIF1A in MDA-MB-231 breast
cancer cells does not significantly change cell number at
either normoxia or hypoxia (1% O2) [50]. It is possible
that the effects of loss of HIF-1a activity on PyMT cell
growth in monolayer culture would be attenuated if
cells were cultured at higher serum levels since MDA-
MB-231 cells were cultured in medium containing 10%
FBS whereas PyMT cell lines were cultured in medium
containing 2% or 5% FBS.
We further demonstrate that primary tumor growth
and survival from distant metastases are dependent
upon epithelial cell intrinsic HIF-1a expression. In stark
contrast to results obtained previously [27], we found
that HIF-1a plays a significant role in the control of pri-
mary PyMT-induced mammary tumor growth under
either standard (50,000-cell input) or limiting dilution
cell transplantation conditions (50- to 500-cell input).
The cause of the control of net mammary tumor growth
by HIF-1a is unclear, although our data suggest that
HIF-1a-dependent control of TIC activity may be a pri-
mary mechanism driving tumorigenesis. The significant
changes in Vegf mRNA expression and microvessel den-
sity observed in early-stage KO tumors may also contri-
bute to the phenotype by furthering restricting tumor
growth once tumors are initiated. In agreement with our
observations, a HIF-1a-dependent effect on tumor
growth was demonstrated recently in both MDA-MB-
231 and MDA-MB-435 breast cancer xenografts [50,51].
Characterization of the expression of luminal (K8/
K18) and myoepithelial (K14/K5) lineage markers in
WT and KO PyMT cells and tumors revealed that fewer
KO cells than WT cells coexpressed K8/K14, primarily
due to loss of K14-positive cells. These results suggest
that loss of HIF-1a activity corresponds with a reduc-
tion in bipotent, stemlike cells in PyMT tumors. The
most dramatic phenotype was the absence of K5-posi-
tive cells in KO cultures and the loss of both K14- and
K5-positive cells in KO tumors. These data are of inter-
est, given the stratification of triple-negative breast can-
cers (TNBCs) into non-basal-like or basal-like subtypes,
based on the expression of both K5 and epidermal
growth factor receptors (EGFRs) in tumors within the
basal-like subtype [52].
TNBC patients with a basal-like classification have
shorter disease-free or overall survival [53,54] and
tumors from TNBC patients with metastatic disease
exhibit higher levels of K5 and EFGR [55]. A potential
influence of HIF-1a on the ability of the K5 and EGFR
biomarkers to predict disease-free survival in basal-like
TNBC is intriguing in light of our observations that, in
cultured cells, EGF stabilizes HIF-1a expression at nor-
moxia and further potentiates hypoxia-inducible expres-
sion of HIF-1a. Although the PyMT model is classified
as a luminal-like cancer [26], late-stage tumors such as
the ones utilized to generate HIF-1a WT and KO cells
are ER- [25]. Subpopulations of both WT cells and WT
tumors were positive for K5.
It has also been observed in luminal breast cancer cell
lines (T47D and MCF7), which contain subpopulations
of ER-/PR-/K5+ cells, that the K5+ cells are enriched
for TIC activity and are resistant to conventional che-
motherapies compared to ER+/PR+/K5- cells [56]. Of
additional relevance to our results regarding the
decreased expression of K5, K14 and markers of EMT,
including Slug, by KO tumors is that hypoxia-dependent
elevation in K5 mRNA levels occurs in a SLUG-depen-
dent manner in MCF7 cells [40]. Furthermore, a statisti-
cally significant correlation was found to exist between
tumors with high SLUG expression and PROM1
(CD133) expression. These tumors also expressed high
levels of carbonic anhydrase IX (CAR9), which is a
known HIF-1 target gene [40].
Recent whole-genome expression profiling of breast
cancers has revealed that the hypoxic response (predo-
minantly through HIF-1a), the EGFR and signal trans-
ducer and activator of transcription 3 (STAT3)
pathways are positively correlated together in TNBCs as
compared to luminal cancers [57]. In support of a func-
tional association between the HIF-1a and EGFR path-
ways in TNBCs, MDA-MB-231 cells treated with
gefitinib were found to exhibit downregulation of HIF-
1a transcriptional activity that corresponded with
decreases in cell viability and migration, whereas resis-
tance to cetuximab or lapatinib therapy was hypothe-
sized to be due to the inability of either drug to
downregulate HIF-1a activity [56]. Taken together,
these observations suggest that targeting the HIF path-
way may be beneficial to TNBC patients, particularly
those patients diagnosed with basal-like TNBC.
Based upon the HIF-1a-dependent control of CD133
expression in MTECs and tumorspheres, as well as the
enrichment of sphere formation in the CD133hi versus
CD133neg populations, we have identified CD133 as a
cell surface marker that may enrich for TICs in the
PyMT model. Antibodies to epitope 2 of CD133
(CD133/2) have been utilized extensively to enrich for
TICs in other solid tumors, particularly in human colon
cancer and gliomas. In contrast, in the normal mam-
mary gland, CD133 is expressed by differentiated ER+
luminal cells, and CD133+ cells exhibit lower regenera-
tive capacity than CD133- cells [58]. Notably, deletion
of Prom1 in a knockout mouse model did not impair
the regenerative capacity of the normal mammary gland,
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but did reduce ductal branching during morphogenesis
by increasing the ratio of luminal to basal cells [59]. Yet,
in the NKI 295 data set, PROM1 expression levels were
found to be lower in ERa+ tumors than in ERa- tumors
[59]. The association of HIF-1a and PROM1 expression
in ER- breast cancers is not surprising, given that
hypoxia is a potent stimulator of ERa degradation
[60,61].
In contrast to observations in the normal mammary
gland, Meyer and colleagues have recently shown that,
in the context of ER- breast cancers, CD133 enriches
for TICs when used in conjunction with CD49f (integrin
a6) and CD44 [62]. Specifically, the CD49f+/CD44
+/CD133hi population identified tumor cells with
enriched sphere-forming and xenografting potential.
Likewise, CD133 has also been shown to enrich for
TICs in the Brca1 conditional mouse [21]. That a mar-
ker of a differentiated normal mammary epithelial cell
could enrich for cells with TIC activity in the context of
breast cancer is also supported by recent evidence from
multiple laboratories that, in BRCA1 basal-like tumors,
the TIC population arises from the luminal lineage
[63-65]. Interestingly, basal-like BRCA1 tumors have
previously been shown to overexpress HIF-1a and
higher HIF-1a levels have been found to be correlated
with decreased disease-free survival [66,67]. Moreover,
Proia et al. found that SLUG promoted a basal-like phe-
notype before and after transformation in BRCA1
tumors [65], which is consistent with our observation
that expression of Slug decreased more than threefold in
HIF-1a-KO PyMT tumors that did not express the
basal markers K5 and K14.
Furthermore, accumulating evidence suggests that dif-
ferentiated cells (lineage-restricted progeny) may reac-
quire stem cell-like potential and tumor-initiating
capacity rather than follow a strict linear hierarchy as
originally proposed for the normal mammary gland. The
plasticity involved in breast stem cell biology is emer-
ging. Two independent groups have observed the spon-
taneous conversion of non-stem cells into stem cells
[68,69]. Likewise, the results of recent lineage-tracing
experiments by researchers in the Blanpain laboratory
have challenged the requirement for a bipotent stem cell
in the postnatal normal mammary gland [70]. Under the
limiting cell conditions routinely used to document the
regenerative capacity of a given cell population, these
authors found that the disruption of the normal lumi-
nal-to-myoepithelial cell ratio is sufficient to stimulate a
unipotent myoepithelial progenitor cell to reacquire a
bipotent progenitor activity that is normally restricted to
the embryonic gland [70]. Yet, how, or if, this model
derived from lineage-tracing experiments can be applied
to TICs during breast tumorigenesis remains unknown.
One mechanism of HIF-1a-dependent control of TIC
may be through regulation of the Notch pathway. Inter-
actions of HIF-1a with the Notch intracellular domain
enhances the regulation of Notch transcriptional targets,
such as the HEY genes, and promotes EMT in breast
cancer [16,71,72]. In addition, in breast cancer,
NOTCH1 and NOTCH4 have been positively correlated
with stemness, and blocking antibodies to NOTCH4
reduces mammosphere formation [72]. In KO tumor-
spheres and early-stage KO tumors, decreased expres-
sion of several members of the Notch pathway,
particularly Notch4 and Hey1, was observed. Changes in
Notch4 are of particular interest because previous stu-
dies have shown that blocking NOTCH4 receptor activ-
ity inhibits tumor formation of xenografted breast
cancer cells, whereas blocking NOTCH1 has less of an
effect [72]. Although a positive correlation between
hypoxia and NOTCH3 expression was previously
described in breast cancer [73], no HIF-1a-dependent
changes in Notch3 were observed in our studies.
HIF-1a-dependent effects on sphere formation effi-
ciency in vitro and TIC activity in vivo were observed
using parental tumor cells without first enriching for a
putative CSC subpopulation based on cell surface mar-
kers. One rationale for this approach is the lack of com-
prehensive information on the markers that define TICs
in the PyMT model. In a similar PyMT tumor cell
transplant paradigm to ours, the population of CD24
(heat stable antigen)hi/CD29(b1-integrin)+/CD61(b3-
integrin)+ cells was found to significantly increase dur-
ing tumor progression, specifically at the transition from
hyperplasia to carcinoma. Greater than 90% of cells
were characterized as CD24hi/CD29+/CD61+ in late-
stage carcinomas, and this population also had enhanced
invasive potential in vitro [19]. More recently, research-
ers in the Visvader laboratory have shown that, in cells
derived from PyMT adenomas (early-stage lesions),
CD14 and c-kit, along with CD49f/CD24, enriches for
cells with colony-forming potential [74].
In addition, the physical stress of flow sorting
decreases cell viability, which therefore directly influ-
ences the estimated TIC frequency as determined
through limiting dilution transplantation. As observed
for the MMTV-Neu model, the TIC frequency of
unsorted cells was 1 in 61, decreasing to 1 in 177 for
cells enriched by sorting [20]. Likewise, for cells isolated
from PyMT adenomas, the TIC frequency was estimated
to be 1 in 556 for unsorted cells, whereas the TIC fre-
quency in Linneg cells following sorting for CD24 was 1
in 648 [74]. Using unsorted cells isolated from late-stage
carcinomas of the PyMT model, we observed a TIC fre-
quency of 1 in 82. It is possible that the TIC frequency
in the PyMT model may vary based upon both the stage
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of progression and subtle differences in technical proce-
dures among laboratories.
The specific cell surface markers that enrich for breast
tumorsphere or TIC activity are also likely to vary in
each mouse model. In the Balb/C p53-/- model, mam-
mary tumor cells double-positive for CD24 and CD29
were found to exhibit TIC activity [22]. In contrast, in
the MMTV-Neu model Sca-1+ cells were found to cor-
relate with sphere formation [75], and CD61 was also
described as a marker that enriched for TICs [20]. How
HIF-1a directly affects various tumor cell subpopula-
tions defined through flow cytometric profiling for the
known murine mammary stem cell markers, or whether
HIF-1a is preferentially expressed in a given subpopula-
tion requires further extensive investigation.
Conclusions
Tumor hypoxia profoundly affects all aspects of tumori-
genesis, including tumor growth, angiogenesis, metasta-
sis and response to chemotherapy and radiation.
Although HIF’s effects are pleiotropic, evidence for the
role of HIF-dependent TICs in controlling these pheno-
types and the solid tumor stem cell niche is increasing.
Notably, a recent report indicated that oxygen tension
can profoundly influence TICs because repetitive cycles
of hypoxia and reoxygenation promoted breast cancer
cell lines to permanently acquire stemlike properties
[76]. Our studies demonstrate that the hypoxic response,
specifically through HIF-1a, is important for controlling
breast cancer stem cell behavior through the regulation
of CD133 and the Notch pathway. These data, together
with previous observations that the HIFs directly med-
iate glioma, lymphoma and AML TIC activity [15,16],
suggest that attenuation of HIF activity may effectively
eradicate TICs in a variety of cancers, leading to
improved therapeutic response and overall survival.
We acknowledge the possibility that HIF-1a may reg-
ulate activity of TICs and differentiated cell lineages
simultaneously within a tumor. For example, HIF-1a
may regulate breast TIC activity in a stemlike cell popu-
lation expressing CD133, but HIF-1a activity may also
be required by differentiated cells that may act to sup-
port TICs through paracrine signaling, perhaps via a
HIF-dependent secreted growth factor such as VEGF.
Whether the EGFR pathway is required for HIF-1a-
dependent regulation of TIC activity, particularly in
basal-like TNBC, also requires further investigation.
Given the pleiotropic role of HIF-1a in tumorigenesis
and metastasis, as well as the increasing evidence that
stem cells may evolve de novo from non-stem cells, tar-
geting both the TIC and non-TIC ("bulk”) populations
in breast cancer is likely necessary to successfully treat
primary breast cancer and to prevent metastasis.
Additional material
Additional file 1: Table S1 Primers and Roche Universal Probe
Library (UPL) 6-carboxyfluorescein-labeled probes utilized in
quantitative RT-PCR assays. Table S2 Primary antibody source and
dilution factors utilized in Western blotting, immunohistochemistry
(IHC), immunofluorescence (IF) and fluorescence-activated cell
sorting (FACS). Anti-a-SMA, anti-a-smooth muscle actin; anti-mouse
CD133-PE, anti-mouse CD133-phycoerythrin; anti-mouse ERa, anti-mouse
estrogen receptor a; anti-mouse CD24-FITC, anti-mouse CD24-fluorescein
isothiocyanate; HRP, horseradish peroxidase; SA-APC, streptavidin-
allophycocyanin. Table S3 Frequency of tumors in recipient mice at
day 62 after limiting dilution transplantation. ELDA, Extreme Limiting
Dilution Analysis; HIF-1a, hypoxia-inducible factor 1a; KO, knockout;
MTEC, mammary tumor epithelial cell; TIC, tumor-initiating cell; WT, wild
type. Table S4 Frequency of tumors in recipient mice at day 112
after limiting dilution transplantation. ELDA, Extreme Limiting Dilution
Analysis; HIF-1a, hypoxia-inducible factor 1a; KO, knockout; MTEC,
mammary tumor epithelial cell; TIC, tumor-initiating cell; WT, wild type.
Table S5 Summary of the percentage and total number of
recipients bearing small tumors at day 112 posttransplant. KO,
knockout; WT, wild type. Table S6 Frequency of tumors in recipient
mice at day 244 after limiting dilution transplantation. ELDA,
Extreme Limiting Dilution Analysis; HIF-1a, hypoxia-inducible factor 1a;
KO, knockout; MTEC, mammary tumor epithelial cell; TIC, tumor-initiating
cell; WT, wild type. Table S7 Summary of the percentage and total
number of recipients bearing small tumors at day 244
posttransplant. KO, knockout; WT, wild type.
Additional file 2: Figure S1 HIF-1a expression increase during
tumor progression in the MMTV-PyMT mouse model and
confirmation of HIF-1a deletion. HS-WCE protein extracts were
prepared from two individual transgenic MMTV-PyMT female mice (FVB/
Nj strain) between 6 and 9 weeks of age. HS-WCE, high-salt whole-cell
extract; MMTV-PyMT, mouse mammary tumor virus polyoma virus middle
T. By palpation, each mouse had at least one mammary gland with
hyperplastic (HP) (palpable as grainy), early-carcinoma (EC) (< 250 mm3)
or late-carcinoma (LC) (> 500 mm3) lesions, which was expected because
tumor progression among glands is asynchronous in this model. Two
independent glands (one from each mouse) per stage were utilized to
prepare HS-WCEs for Western blotting. As shown, HIF-1a expression
generally increased during progression and was most abundant in late-
stage carcinomas. Included as controls were HS-WCEs prepared from
wild-type (WT) and knockout (KO) mammary tumor epithelial cells
(MTECs) grown to 80% confluence, followed by hypoxia exposure for 6
hours at 0.5% O2. A cross-reactive material (CRM) band at about 76 kDa
was detectable when lot E2 of NB 100-479 of the anti-mouse HIF-1a
primary antibody (Novus Biologicals, Littleton, CO, USA) was used. KO
cells were transduced twice with adenovirus-Cre in monolayer culture at
80 to 100 plaque-forming units/cell to achieve > 99% deletion efficiency
as determined by qRT-PCR and Western blot analysis. Figure S2 HIF-1a
expression increases in response to EGF treatment at normoxia,
and EGF prolongs HIF-1a stabilization at hypoxia. Wild-type (WT)
mammary tumor epithelial cells (MTECs) were either cultured in
complete growth medium (containing 5% fetal bovine serum, FBS + 5
μg/ml insulin + 10 ng/ml epidermal growth factor, EGF) or in medium
supplemented only with 2% FBS for at least five passages prior to
replating to test the effect of EGF treatment on HIF-1a expression. Cells
grown to 80% confluence were incubated at hypoxia for the number of
hours indicated (3, 6 or 24). All cells were exposed to hypoxia beginning
24 hours prior to harvest (the t = 0 time point) such that cells at the t =
0 time point (normoxic control) were harvested at the same time as the
t = 24 hours hypoxia time point. Cells were exposed to hypoxia for the
indicated number of hours prior to removal from culture and the
immediate preparation of high-salt enriched whole-cell extracts. HIF-1a
was detected using lot E2 of NB 100-479 (Novus Biologicals, Littleton,
CO, USA). Figure S3 Histology of HIF-1a WT and KO end-stage PyMT
tumors. H & E-stained sections of end-stage tumors (> 750 mm3)
derived from wild-type (WT) or knockout (KO) cells are shown. HIF-1a,
hypoxia-inducible factor 1a; PyMT, polyoma virus middle T. The WT
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tumors typically contained more extensive areas of necrosis than the KO
tumors. One representative tumor per genotype was imaged using 5 ×,
20 × and 63 × lens objectives of a Leica DM6000 upright microscope
(Leica Microsystems, Buffalo Grove, IL, USA) with a SPOT camera (SPOT
Imaging Solutions, Sterling Heights, MI, USA) for final original
magnifications of ×50, ×200 or ×630, respectively. Scale bar = 50 μm.
Digitally scanned whole slides of H & E-stained WT and KO tumor
sections were captured using the Aperio ScanScope system (Aperio,
Vista, CA, USA). Whole-slide images have been posted to a public
database, which may be accessed using instructions provided in the
Additional methods. Figure S4. Ki67 and activated caspase 3
immunostaining in end-stage PyMT tumors. Paraffin-embedded,
formalin-fixed tissue sections from wild-type (WT) and knockout (KO)
tumors (> 500 to 750 mm3) were immunostained with either Ki67 or
activated caspase 3 antibodies, and immunoreactive complexes were
detected using the VECTASTAIN Elite ABC Kit (Vector Laboratories,
Burlingame, CA, USA) and developed with ImmPACT DAB substrate
(diaminobenzidine; Vector Laboratories), followed by counterstaining with
Harris hematoxylin. PyMT, polyoma virus middle T. Scale bar = 100 μm.
Figure S5 Expression of p63 and ERa in WT and KO end-stage
PyMT tumors. Representative results of p63 and estrogen receptor a
(ERa) immunostaining in wild-type (WT) and knockout (KO) tumors (n =
4/genotype), along with expression observed in normal virgin mammary
glands, which served as the positive control (n = 2 FVB strain mice about
8 weeks of age). HIF-1a, hypoxia-inducible factor 1a. Original
magnification, ×200; scale bar = 50 μm. Black arrows point to examples
of positive cells. No obvious changes in p63 expression or localization
were detected between WT and KO tumors, whereas p63 was located
basally within the virgin mammary ductal tree, as expected. No
immunoreactivity for ERa was detected in end-stage WT or KO tumors
(which were derived from late-stage carcinomas of the MMTV-PyMT
transgenic mouse), whereas almost all ductal epithelial cells in the virgin
normal mammary gland expressed ERa as previously reported [77].
Figure S6 Overview of the mean fold enrichment in SFE in WT cells
compared to KO cells. (A) to (C) Bar graphs represent the mean fold
enrichment of sphere formation efficiency (SFE) ± SEM for each
generation (three biological replicates per genotype per generation in
(A) and (B)) or for specific genotype-oxygen tension comparisons (C).
Adeno-Bgal, adenovirus b-galactosidase; DF, double floxed; HIF, hypoxia-
inducible factor 1a; KO, knockout; PyMT+, polyoma virus middle T-
positive; WT, wild type. (C) The mean fold change in SFE observed for
specific comparisons between genotype and oxygen tension is
presented (nor, normoxia; hyp, hypoxia) (wild-type normoxia (WT nor) to
knockout (KO) nor, n = 4; WT hypoxia (WT hyp) to KO hyp, n = 3; WT nor
to WT hyp, n = 5; KO nor to KO hyp, n = 3). The SFE is a percentage and
was determined as follows: [(number of cells capable of forming
spheres)/(total number of single cells plated) × 100]. Figure S7 HIF-1a
expression in tumorspheres cultured acutely or chronically at
hypoxia. Wild type (WT) or knockout (KO) tumorspheres were originally
derived from single cells plated into ultralow adhesion dishes and
cultured at normoxia. HIF-1a, hypoxia-inducible factor 1a. A subset of
WT and KO tumorspheres (80 to 100 μm in size) were then transferred
from normoxic to hypoxic culture (0.5% O2) for the duration of
incubation, which was either acute (6-hour exposure) or chronic (> 4
days’ exposure). Spheres were then isolated, high-salt whole-cell extract
(HS-WCE) was prepared and HIF-1a expression levels were evaluated by
Western blot analysis (input of 1 μg HS-WCE/lane) using lot M1 of Novus
100-479 (Novus Biologicals, Littleton, CO, USA), which produced more
cross-reactive material (CRM) bands than previously observed with lot E2.
Figure S8 Gating strategy for sorting CD133hi versus CD133neg
populations from mammary tumors originating in PyMT+
transgenic females. After being stained, cells resuspended in flow buffer
were subjected to flow sorting on a FACSAria cell sorter (BD Biosciences,
San Diego, CA, USA) at the University of Tennessee Health Science
Center Flow Cytometry and Sorting Core. Forward scatter (FSC) and side
scatter (SSC) gates were set to exclude particulate debris, followed by
gating for singlets based on FSC area (FSC-A) and FSC height (FSC-H).
Singlet events were determined to be viable by gating against cells that
stained positive with SYTOX Blue (Molecular Probes/BD Biosciences,
Eugene, OR, USA) or 7-AAD (BD Pharmingen, San Diego, CA, USA). Linneg
live singlets were selectively gated based on the absence of expression
of the mouse lineage marker panel (BD Biosciences) that was
supplemented with CD31 (BD Biosciences) to exclude endothelial cells.
The gating to enrich for CD133-PEhi cells was manually set based on the
isotype matched control antibody. PyMT+, polyoma virus middle T-
positive; APC, allophycocyanin; IgG, immunoglobulin G; Lin,
hematopoietic lineage panel; PE, phycoerythrin. Figure S9 Comparison
of WT and KO tumor-initiating potential at day 62 posttransplant.
The percentage of FVB recipients (tumor-positive recipients/total number
of recipients successfully transplanted) that developed a palpable mass ≥
5 mm in diameter was compared on day 62 after injection of wild type
(WT) or knockout (KO) cells. The asterisks indicate a statistically significant
difference between genotypes per cell density determined by Fisher’s
exact test. Figure S10 Mean WT and KO tumor volume in the 200-
and 500-cell input cohorts up to day 36 posttransplant. Comparison
of mean tumor volume ± SEM when 500 or 200 wild type (WT) or
knockout (KO) cells were injected into a single, cleared inguinal
mammary fat pad per recipient. All recipients in the 500- and 200-cell
input cohorts were euthanized on day 36 posttransplant to obtain tissue
sections and RNA during the early stages of tumor outgrowth. The
number of recipients with palpable masses per genotype per density is
reviewed in Table 1. Figure S11 Mean tumor volume in the 100-cell
WT and KO cohorts up to day 112 posttransplant. Comparison of
wild-type (WT) and knockout (KO) mean tumor volume ± SEM over time
when 100 cells were injected into a single, cleared inguinal mammary fat
pad. The decrease in mean tumor volume observed at day 112 for the
100-cell KO group is due to the exclusion of a subset of individual
recipients in this cohort that developed tumors > 500 mm3. These
recipients were subjected to surgical resection of the primary tumor
between days 96 and 112 posttransplant. Figure S12 Mean WT and KO
tumor volume in the 10-, 25- and 50-cell input cohorts up to day
112 posttransplant. Comparison of wild type (WT) and knockout (KO)
mean tumor volume ± SEM over time when 10, 25 or 50 WT or KO cells
were injected into a single, cleared inguinal mammary fat pad. The
decrease in mean tumor volume observed at day 112 for the 100-cell KO
group is due to the exclusion of a subset of individual recipients in this
cohort that developed tumors > 500 mm3. These recipients were
subjected to surgical resection of the primary tumor between days 96
and 112 posttransplant.
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